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Abstract
In Brazil, epizootics among New World monkey species may indicate circulation of yellow fever (YF) virus and provide early
warning of risk to humans. Between 1999 and 2001, the southern Brazilian state of Rio Grande do Sul initiated surveillance
for epizootics of YF in non-human primates to inform vaccination of human populations. Following a YF outbreak, we
analyzed epizootic surveillance data and assessed YF vaccine coverage, timeliness of implementation of vaccination in
unvaccinated human populations. From October 2008 through June 2009, circulation of YF virus was confirmed in 67
municipalities in Rio Grande do Sul State; vaccination was recommended in 23 (34%) prior to the outbreak and in 16 (24%)
within two weeks of first epizootic report. In 28 (42%) municipalities, vaccination began more than two weeks after first
epizootic report. Eleven (52%) of 21 laboratory-confirmed human YF cases occurred in two municipalities with delayed
vaccination. By 2010, municipalities with confirmed YF epizootics reported higher vaccine coverage than other
municipalities that began vaccination. In unvaccinated human populations timely response to epizootic events is critical
to prevent human yellow fever cases.
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Introduction
Yellow fever (YF) is a disease caused by yellow fever virus (YFV),
a member of the Flaviviridae family. The disease is considered
endemic in parts of Africa and South America. Due to its varied
clinical presentation and limited surveillance, yellow fever is under-
reported: annually, approximately 5,000 cases are reported to
WHO (World Health Organization) from Africa and 300 cases from
South America but true incidence is believed to be 10–50 fold
higher [1]. The natural transmission cycle of YF involves tree-hole
breeding mosquitoes and a wide array of monkeys, apes and
marmosets [1]. While primate species in Africa rarely develop fatal
disease following YFV infection [2], several species of New World
monkeys in the Americas are susceptible to severe, fatal YF disease.
In the Americas, deaths of susceptible non-human primates are
sentinel events that may indicate presence of YFV in a specific
geographic location or environment and surveillance for such events
is an important tool to prevent human disease [3]. The goal of
surveillance for deaths among non-human primates is to provide an
early warning of risk of YFV transmission to humans, for rapid
implementation of vaccination and prevention strategies. However,
there have been few reports on how epizootic surveillance has been
used to inform YF vaccination in human populations.
In Brazil, YF caused major urban epidemics and was considered
a public health scourge in Brazilian cities until successful vector
control and human vaccination strategies eliminated urban
transmission in 1942 [4]. However, the existence of a sylvatic
cycle of YFV transmission involving non-human primates was
described in the 1930s [5]. Since that time, sporadic human cases
and outbreaks have resulted from human activity in endemic areas
and expansion of viral transmission to previously unaffected
regions. The coastal area of Brazil is generally considered free of
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YF, including states on the northern, southeastern and southern
coasts [2]. Mainly in rural areas, the sylvatic cycle has been
maintained by transmission among non-human primates and
mosquito vectors. Some New World monkeys, e.g. howler monkeys
(genus Alouatta) are extremely susceptible to YFV [6] and develop
fatal disease, similar to humans [1]. There are records of epizootics
characterized by substantial mortality in howler monkeys popu-
lations due to this disease [7–13].
Surveillance for YF detection in non-human primates was
initiated in the state of Rio Grande do Sul, Brazil in 1999, initially
as a passive strategy. Active surveillance began in 2001 following
detection of YFV in the northwestern part of the state (bordering
Argentina) [11,14,15] and vaccination of residents in surrounding
municipalities. Between December, 2002 and September, 2008,
no evidence was found of YFV circulation or of immunity to YFV
in blood specimens from more than 200 captured howler monkeys
of Alouatta species or evidence of YFV in more than 2,000
mosquitoes (including Haemagogus leucocelaenus) [16]. Seven years
after active surveillance began, a rapidly-spreading YF outbreak in
the state between October, 2008 and June, 2009 [7,17]. The
coincident YF epizootic in non-human primates was the largest
ever documented, with more than two-thirds of specimens from
non-human primates testing positive for YFV infection [7,17].
The YF outbreak provided the opportunity to evaluate surveil-
lance for epizootic events involving deaths of non-human primates.
We assessed timeliness of notification of non-human primate deaths
in relation to the occurrence of confirmed human cases, vaccine
coverage and timing of YF vaccination in municipalities in the state
of Rio Grande do Sul during the YF outbreak.
Methods
Ethics statement
This study involved analysis of routinely collected surveillance
data and did not require ethical review according to the Brazilian
National Committee for Ethics in Research.
Personally identifiable information was available only to
surveillance officers and was not used in this study.
Setting
The state of Rio Grande do Sul is the southernmost state in
Brazil, bordering Uruguay to the south and Argentina to the west
(Figure 1). It occupies an area of 268,782 km2 and has 10,695,532
inhabitants [18]. The state is divided in 496 municipalities, and the
capital is Porto Alegre (1,409,939 inhabitants).
Surveillance for YF in non-human primates
An epizootic is defined as a disease that appears as new cases in
a given animal population over a short period of time in a defined
geographical area. Yellow fever epizootics are confirmed based on
laboratory evidence of YFV infection in specimens collected from
affected non-human primates or mosquitos. For rapid implemen-
tation of control measures, suspected YF epizootics are classified
based on epidemiologic linkage, when four or more non-human
primate deaths are identified in areas with evidence of YFV
circulation, 10 or more dead animals are found in bordering areas
or non-human primate die-offs occur in environments similar to
those with evidence of YFV circulation. Evidence of YFV
circulation included probable locations of infection of confirmed
human YF cases, confirmed YF epizootics or YFV detection in
mosquitoes collected during case or epizootic investigations.
Passive surveillance for epizootic disease in non-human
primates is conducted as previously described [7]. Briefly, sightings
of sick or dying monkeys and discovery of non-human primate
carcasses were reported to the passive surveillance system through
municipal or state health authorities and investigated by municipal
health departments.
Active surveillance for evidence of YFV circulation included
capture of forest-dwelling primates for collection of blood and sera,
and collection of mosquitoes for identification and virus isolation
[19]. Active surveillance was employed following investigations of
non-human primate deaths when biological specimens could not
be obtained or in ‘‘silent’’ areas with no information about
presence of YFV or antibodies in non-human primate populations.
Outbreak response
Enhanced surveillance was conducted in areas bordering those
with evidence of YFV circulation or similar environmental
features. Enhanced surveillance included active case finding,
immediate investigation of non-human primate deaths and
expedited specimen processing. Findings of non-human primate
carcasses in other municipalities triggered control vaccination of
the human population within a 2 km radius for events in a rural
area or 300 m in urban areas pending laboratory confirmation of
the presence of YFV. During the outbreak response, YF
vaccination was recommended immediately from 9 months of
age in municipalities with evidence of YFV circulation (‘‘affected
areas’’) and all the surrounding municipalities which have borders
with municipalities with confirmed YFV circulation (‘‘expanded
areas’’).
Classification of human YF cases
The suspected case definition for human YF was a patient with
sudden onset of fever accompanied by jaundice or hemorrhage.
Patients with recent YF vaccination were investigated for possible
adverse events of vaccination, including YF vaccine-associated
acute viscerotropic disease. Suspected cases with laboratory
evidence of YF infection or exposure during the incubation period
to affected areas without an alternative diagnosis were classified as
Author Summary
Yellow fever (YF) is a viral hemorrhagic disease that affects
humans as well as several species of non-human primates,
especially New World monkeys found in South America.
Yellow fever virus (YFV) is maintained in a natural cycle
involving tree-hole breeding mosquitoes and non-human
primates hosts. Because YF is often fatal in susceptible
New World monkey populations, sudden die-offs of New
World monkeys or epizootics can signal YFV circulation in
an environment where humans may be exposed. Surveil-
lance for such events is an important tool to prevent
human disease. The state of Rio Grande do Sul in southern
Brazil was one of the first states to conduct passive and
active surveillance for yellow fever virus circulation in non-
human primates. During a rapidly-spreading YF outbreak
in 2008–2009, surveillance for epizootics involving non-
human primates informed vaccination of human popula-
tions in areas previously free of YF. In this study, we
analyzed surveillance data to evaluate vaccine coverage,
timeliness of notification, investigation and confirmation of
epizootic events in relation to occurrence of human cases
of YF. Epizootic surveillance is useful for directing the
efforts of vaccine distribution. Prevention of YF in
susceptible human populations requires immediate risk
communication and implementation of vaccine recom-
mendations after the first reports of epizootic activity
when YF is suspected.
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confirmed cases. Laboratory evidence of YF infection included
virus isolation [20], viral antigen identification [21,22], detection
of YF specific immunoglobulin M (IgM) by immunoassay [23] or
hemagglutination inhibition tests [20]. The diagnosis of YF was
discarded in suspect cases without laboratory evidence of YF
infection or exposure to affected areas, or with confirmed diagnosis
of another illness.
During investigations of reported deaths of non-human
primates, field teams rapidly assessed vaccination coverage among
residents of surrounding areas and carried out active searches for
suspected cases of YF among symptomatic individuals.
The probable place of infection for human cases was defined as
an area with epidemiological evidence of YFV circulation, where
the human case was exposed during the incubation period.
Data collection and analysis
For municipalities in which vaccination against YF was
recommended as of July 5, 2009, we calculated the number of
days from first report of deaths among non-human primates to
laboratory confirmation of YFV, date of vaccine recommendation
or onset of illness for confirmed human YF cases. We defined as
timely vaccine recommendations within two weeks (14 days) of first
reported deaths among non-human primates. We excluded one
human case identified more than one year after disease occurrence
during review of surveillance data.
Data on the number of YF vaccine doses administered in each
municipality by month during the outbreak period were obtained
from the Rio Grande do Sul state immunization program.
Administrative estimates of YF vaccine coverage were obtained
by dividing the cumulative number of doses administered
(including doses administered prior to the outbreak from January,
2001 through October, 2008) by the total population of
municipalities with YF vaccine recommendation.
Results
Prior to the beginning of the outbreak in October, 2008,
vaccination against YF was recommended in 52 municipalities,
with a total population of 531,163. By June, 2009, after eight
months of YFV spread, YF vaccination was recommended in 293
municipalities, with a total population of 6.9 million inhabitants
(Table 1).
Of the 293 municipalities in which yellow fever vaccination was
recommended by July, 2009, 67 (23%) were classified as ‘‘affected
areas’’ (based on confirmed YFV circulation during the outbreak
period) and 226 (77%) as ‘‘expanded areas’’ (Figure 2). Of these,
61 (21%) municipalities reported monkey deaths without labora-
tory evidence of YFV circulation and 165 (56%) were adjacent to
municipalities with YFV circulation but had no reports of monkey
deaths during the outbreak period. In 26 additional municipalities,
epizootics were reported but laboratory and environmental
investigations did not suggest YFV circulation and vaccination
was not recommended.
Between November 30, 2008 and July 5, 2009, vaccination
against YF was initiated in 241 municipalities (Figure 3). Among
67 municipalities with confirmed YFV circulation, implementation
of YF vaccine recommendations was considered timely in 39
(58%): YF vaccine was recommended before the outbreak in 23
municipalities (11 with vaccination since 2001) while in 16,
recommendations were implemented within 2 weeks of the first
report of epizootic activity. In 28 (42%) of 67 municipalities with
Figure 1. Map showing the state of Rio Grande do Sul, Brazil. The Brazilian state of Santa Catarina lies to the north, Uruguay to the south,
Argentina to the west and the Atlantic Ocean to the east.
doi:10.1371/journal.pntd.0002741.g001
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confirmed YFV circulation, vaccine recommendations were
implemented more than 2 weeks (range 15 to 138 days) after
first reported epizootic activity.
During the 9-month period, a total of 118 suspected human
cases of YF were reported from 59 municipalities: 21 (18%) were
confirmed based on laboratory and epidemiologic evidence, while
YF was discarded in 97 (82%) without laboratory evidence of YF
infection. Case-fatality among confirmed YF cases was 43% (9 of
21). None of the confirmed cases had documented history of YF
vaccination. All confirmed human cases had been exposed to
forested areas and, consequently, to the presence of sylvatic
vectors, including Haemagogus leucocelaenus. Enhanced surveillance
did not identify the presence of other mosquito vectors, including
H. spegazzinii, H. janthinomys or Sabethes sp. Specimens from human
cases were collected an average of 10 days (range, 2 to 17 days)
after reported onset of symptoms and YFV infection was
confirmed by laboratory testing from 13 to 53 days after symptom
onset.
Nine municipalities were identified as probable locations of
infection for 21 confirmed human YF cases. Of these, deaths of
non-human primates were reported in eight (89%) municipalities
12 days to two months prior to onset of illness in persons with
confirmed YF (Table 2). In two municipalities in the northwestern
part of the state (each the probable location of infection for one
human case) in which vaccination had been recommended since
2001, one case occurred in a recently arrived resident and one in a
visitor to the area. Although in both cases family members
reported being vaccinated, neither case patient was aware of YF
vaccine recommendations in the area. In four other municipalities
in the northwestern part of the state, YF vaccination was
recommended within 7 days of the first report of deaths among
non-human primates, before results of laboratory testing con-
firmed YFV epizootics. In two municipalities in the central part of
the state (Santa Cruz do Sul and Vera Cruz), probable locations of
infection for 11 human cases, vaccination began more than two
months after deaths of non-human primates were first reported.
Specimens collected in the municipality following initial investi-
gations tested negative for the presence of YFV (Table 2).
By the end of February, 2009, more than 1.6 million doses of
YF vaccine had been administered in municipalities in which
vaccine was recommended, with a total population of 1.8 million.
Rural areas were prioritized for vaccination. By July, 2009, more
than 4.2 million doses had been administered, but the total
population in municipalities with YF vaccine recommendation
had jumped to 6.9 million, resulting in lower estimates of
administrative coverage. Estimated coverage in more populous
urban areas lagged behind coverage in rural areas. By the end of
2010, administrative coverage of YF vaccine in the area where
vaccination was recommended was greater than 80%. Of 67
municipalities with confirmed YF epizootics during the 2008–09
outbreak, 41 (69%) reported administrative vaccination coverage
of 90% or greater, versus 124 (55%) of 226 municipalities without
confirmed YF epizootics during the outbreak.
Discussion
Our analysis of the vaccination response to a YF outbreak in
southern Brazil in 2008–2009 highlights challenges of using
epizootic surveillance as an early warning system for YF in
humans. Delay in detection or confirmation of YF epizootics may
have resulted in late initiation of vaccination strategies in several
municipalities with documented YFV transmission. Reporting of
suspected epizootics and vaccination activities occurred most
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epizootic activity in 2001 and 2002, where many professionals had
received training on YF surveillance. However, the rapid spread of
YFV to areas previously free of the virus [7], where YF vaccination
was not recommended, overwhelmed public health services,
affecting the timeliness of the sampling and laboratory confirmation
of YFV circulation. Even when specimens were obtained, labora-
tory confirmation by reference laboratories of the presence of YFV
required a minimum of 13 days. Immunization strategies take time
to reach high coverage, and vaccine-induced immunity develops
over 7–14 days [1]. Early in an outbreak, information from
epizootic surveillance may be most useful to identify populations at
highest risk of YFV exposure to prioritize vaccination and other
prevention strategies, including personal protection.
In two municipalities that accounted for more than 50% of
human cases, detection of YFV in non-human primates was
delayed. Despite collection of specimens from non-human
primates prior to occurrence of human cases, vaccination was
not initiated until later specimens tested positive for YFV. Delayed
initiation of vaccination in these municipalities where YF vaccine
had not been recommended previously may have contributed to
higher numbers of people infected in this area. Prevention of
human YF cases requires immediate risk communication and
implementation of vaccine recommendations after the first reports
of epizootic activity when YF is suspected. Based on epizootic
surveillance, YF vaccination was recommended in 165 munici-
palities in ‘‘expanded areas’’ without any reports of dead monkey
sightings, as well as 61 municipalities in which epizootic events
were not confirmed to be yellow fever. By defining outlying areas
as ‘‘at risk’’, authorities did not wait to confirm YFV circulation
before initiating vaccination activities.
Figure 2. Temporal and geographic spread of yellow fever epizootics involving deaths of non-human primates, Rio Grande do Sul,
Brazil, October, 2008 to June, 2009. (Shading corresponds to municipalities with confirmed yellow fever epizootics in non-human primates).
doi:10.1371/journal.pntd.0002741.g002
Figure 3. Expansion of yellow fever vaccination recommendations, Rio Grande do Sul, Brazil, 2008—2011. Municipalities in which YF
vaccination was recommended (shaded area) by timing of recommendation.
doi:10.1371/journal.pntd.0002741.g003
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Investigation of reported monkey deaths during the outbreak
provided evidence of extensive YF epizootics in non-human
primates [7]. In six months, YFV circulation in monkeys spread
more than 600 km from west to east, spreading from 2
municipalities with confirmed circulation of YFV to 67 munici-
palities [7,17]. Prior to the epidemic, active surveillance for the
presence of YFV and other arboviruses among howler monkeys
(Alouatta sp.) identified no immunity to YFV in this population
[16]. However, active surveillance identified YFV-antibodies in
howler monkey captured in November, 2009, several months after
the outbreak period (unpublished data). Data from the investiga-
tions of epizootic activity during this outbreak provided new
information about YFV transmission in susceptible howler
monkey populations. Further study is needed to understand how
YFV is spread between troops of howler monkeys in areas
susceptible to YFV circulation and how environmental factors
influence YFV occurrence and spread.
In 2011, following the epidemic, the Rio Grande do Sul state
health department in coordination with the Brazilian Ministry of
Health recommended YF vaccination in an additional 169
municipalities (Figure 3), leaving only 34 (7%) of 496 municipal-
ities in the state without vaccine recommendation. The decision to
extend YF vaccination to previously unaffected municipalities was
based on the rapid spread of YFV circulation in 2008/2009,
environmental characteristics, population movements and discus-
sions with YF experts and scientific advisory committees. Better
communication of YF recommendations to travelers are also
needed; two of the human cases were probably infected with YF
virus in areas in which vaccination had been recommended since
2001, yet neither was aware of vaccine recommendations.
The purpose of surveillance for YFV infection in non-human
primates is to prevent YF cases and deaths among humans. In Rio
Grande do Sul, surveillance in non-human primates was unable to
predict the 2008–2009 outbreak or the rapid spread of YFV
transmission, although it detected YFV circulation in non-human-
primates in October, 2008 before human cases occurred. Also,
active surveillance prior to the outbreak identified a susceptible
population of non-human primates. During the outbreak, surveil-
lance for epizootic activity allowed health authorities to monitor
virus spread and informed vaccination strategies. In addition,
surveillance for epizootics in non-human primates may have
averted human cases by alerting the public to the risk of YF and
intensifying vaccination efforts, although the number of human
cases prevented through vaccination is unknown. Unfortunately,
we had different levels of response according to the preparedness
of municipalities and the familiarity of the various regions of the
state with this type of emergency. The epidemic of 2008–2009 hit
areas of the state in which we had no information on any previous
occurrence of YF. Active surveillance for YFV infection in non-
human primates in the state also developed capacity by training
over 300 health professionals from Rio Grande do Sul and other
Brazilian states, leading to improved reporting and investigation of
epizootic events. Continued monitoring and evaluation of
surveillance for YF in non-human primates in Brazil is essential
to improve performance. Communication strategies to inform
persons at risk of exposure to sylvatic yellow fever may also
encourage reporting of epizootic events, to improve rapid
detection and response to future YF outbreaks.
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human cases Period of illness onset
Augusto Pestana 28 Nov 08 0 13 3 Dec 08 1 10 Dec 08
Santo Angelo NR NA NA 3 Dec 08 3 18 Dec 08–14 Jan 09
Pirapo 27 Nov 08 5 25 2001 2 29 Dec 08–1 Jan 09
Joia 1 Dec 08 0 29 3 Dec 08 1 30 Dec 08
Bossoroca 1 Dec 08 1 22 2001 1 31 Dec 08
Ijui 28 Nov 08 0 14 3 Dec 08 1 5 Jan 09
Espumoso 31 Dec 08 6 Inc 7 Jan 09 1 12 Jan 09
Santa Cruz do Sul 21 Jan 09 44* 64 25 Mar 09 7 9 Mar–25 Apr 09
Vera Cruz 21 Jan 09 65* 82 25 Mar 09 4 15 Mar–26 Mar 09
Dates of reported deaths or epizootics among non-human primates and onset of illness for confirmed human yellow fever cases in nine municipalities identified as the
Probable Place of Infection for confirmed cases, Rio Grande do Sul, Brazil, October, 2008 to June, 2009.
* Note: Denotes interval (in days) from first reported epizootic to collection of YFV-positive specimens. No specimens were obtained from initial investigations on 21
January 2009 in Santa Cruz do Sul and Vera Cruz. Specimens collected on 3 and 14 February from Santa Cruz do Sul and on 19 February 2009 from Vera Cruz tested
negative for the presence of YFV.
doi:10.1371/journal.pntd.0002741.t002
Yellow Fever Surveillance in Non-Human Primates
PLOS Neglected Tropical Diseases | www.plosntds.org 6 March 2014 | Volume 8 | Issue 3 | e2741
References
1. Monath TP (2001) Yellow fever: an update. Lancet Infect Dis 1: 11–20.
2. Jentes ES, Poumerol G, Gershman MD, Hill DR, Lemarchand J, et al. (2011)
The revised global yellow fever risk map and recommendations for vaccination,
2010: consensus of the Informal WHO Working Group on Geographic Risk for
Yellow Fever. Lancet Infect Dis 11: 622–632.
3. Pan American Health Organization (2005) Control of Yellow Fever: Field
Guide. Washington, D.C.: PAHO. 30 p.
4. Soper FL (1963) The elimination of urban yellow fever in the Americas through
the eradication of Aedes aegypti. Am J Public Health Nations Health 53: 7–16.
5. Soper F (1936) Jungle yellow fever. A new epidemiological entity in South
America. Revista de Hygiene e Saúde Pública 10: 107–144.
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primatas não humanos. Brası́lia, Brazil: National Health Foundation (FU-
NASA), Ministry of Health. 56 p.
20. Beaty B, Calisher C, Shope R (1989) Arboviruses. In: Schmidt N, Emmons R,
editors. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections,
6th edition. Washington, D. C. : American Public Health Association. pp. 797–
855.
21. De Brito T, Siqueira SA, Santos RT, Nassar ES, Coimbra TL, et al. (1992)
Human fatal yellow fever. Immunohistochemical detection of viral antigens in
the liver, kidney and heart. Pathol Res Pract 188: 177–181.
22. Hall WC, Crowell TP, Watts DM, Barros VL, Kruger H, et al. (1991)
Demonstration of yellow fever and dengue antigens in formalin-fixed paraffin-
embedded human liver by immunohistochemical analysis. Am J Trop Med Hyg
45: 408–417.
23. Kuno G, Gomez I, Gubler DJ (1987) Detecting artificial anti-dengue IgM
immune complexes using an enzyme-linked immunosorbent assay. Am J Trop
Med Hyg 36: 153–159.
Yellow Fever Surveillance in Non-Human Primates
PLOS Neglected Tropical Diseases | www.plosntds.org 7 March 2014 | Volume 8 | Issue 3 | e2741
